Recombinant Human Soluble Thrombomodulin Attenuates Hepatic Ischemia and/or Reperfusion Injury by Inhibiting Leukocyte Accumulation in Mice With Normal and Fatty Liver

• Published in: Transplantation proceedings 2018-11, Vol.50 (9), p.2807-2814
• Main Authors: Fujii, T., Kuriyama, N., Hayasaki, A., Iizawa, Y., Tanemura, A., Kato, H., Murata, Y., Azumi, Y., Kishiwada, M., Mizuno, S., Usui, M., Sakurai, H., Isaji, S.
• Format: Article
• Language: English
• Subjects: Animals; Fatty Liver - pathology; Humans; Leukocytes - drug effects; Leukocytes - metabolism; Liver - drug effects; Liver - pathology; Male; Mice; Mice, Inbred C57BL; Organ Preservation - methods; Reperfusion Injury - pathology; Thrombomodulin
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2018.03.044

In an attempt to increase the number of donor livers, there has been an increased use of marginal donor livers, such as steatotic (fatty) livers that increase susceptibility to ischemia and reperfusion injury (IRI). Inflammatory cell accumulation has a greater role in IRI in steatotic liver than in normal liver. Although the recombinant human soluble thrombomodulin (rhsTM) attracts attention as a new treatment for disseminated intravascular coagulation, the therapeutic efficacy of rhsTM in hepatic IRI remains uncertain, especially in fatty livers. We aimed to demonstrate the effect of rhsTM on hepatic IRI using well-established in vivo experimental models with steatotic liver. C57/BL6 mice were divided into 2 groups: normal liver (NL) group and fatty liver (FL) group, in which the steatotic liver was induced by high-fat diet for 9 weeks. The mice in the NL and FL groups were premedicated with venous injection of rhsTM (TM) or saline (Control) as control groups. All 4 groups (NL-Control vs NL-TM, FL-Control vs FL-TM) were subjected to partial hepatic warm ischemia followed by reperfusion. rhsTM significantly attenuated liver injury in the FL group as well as the NL group, as evidenced by transaminase levels and histologic finding after hepatic IRI. rhsTM remarkably decreased the accumulation of inflammatory cells, such as macrophages and neutrophils, in both NL and FL tissue after IRI. Furthermore, rhsTM depressed mRNA and protein expressions of adhesion molecules such as intracellular adhesion molecule-1 and vascular cell adhesion molecule-1 in both NL and FL groups after IRI. Our results demonstrate that rhsTM has a protective effect on fatty liver as well as normal liver after hepatic IRI. They also suggest that rhsTM contributes to attenuation of leukocyte accumulation caused by depressing expressions of adhesion molecules that facilitate accumulation of leukocytes in liver tissue in hepatic IRI. •High-fat diet induced macrosteatosis resembling human obesity.•Recombinant human soluble thrombomodulin attenuated hepatic ischemia and reperfusion injury (IRI) in both normal and fatty liver.•Recombinant human soluble thrombomodulin depressed leukocyte accumulation and activation after IRI.•Recombinant human soluble thrombomodulin depressed the expressions of adhesion molecules in the livers after IRI.